Brain tumor patients at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust received prolonged courses of chemotherapy, with some people undergoing treatment for over 10 years, with little clinical benefit. This was found in a review conducted by the Royal College of Physicians, which was published on 18 November, 2026.
The review looked at the treatment of patients under Professor Ian Brown (referred to in the report as ‘Dr Y’) and found serious issues in the inappropriate prescription of chemotherapy and poor clinical and managerial oversight, meaning some patients received chemotherapy for a long period of time, with insufficient review.
Temozolomide (TMZ) is a common form of chemotherapy given to certain brain tumors, including glioblastoma. The number of courses varies depending on the individual, but normally a total of 6 cycles is recommended following initial treatment for people with glioblastomas. The review found concerns that some patients received far more cycles than recommended without sufficient reason.
The RCP reviewed 20 cases. Fifteen cases were found to have received unsatisfactory care. Five cases were found to require improvement. In three cases, the diagnoses were considered insecure.
Prolonged treatment: People received multiple cycles of TMZ with little evidence to suggest it was appropriate. The RCP also identified multiple cases in which treatment continued despite clear evidence of toxicity and/or deterioration in patients' conditions, with little or no evidence of benefit.
Incorrect diagnosis: Some people were given chemotherapy unnecessarily due to receiving incorrect aggressive brain tumor diagnoses.
Lack of informed consent: People weren’t appropriately informed about the risks, benefits, and unusual duration of treatment in some cases.
Poor clinical management: Other clinicians, pharmacists, and multidisciplinary teams were not provided with good opportunities to raise concerns.
The review identified different levels of harm among the patients. Six cases involved severe harm, five involved moderate harm, and eight involved low levels of harm. In one case, the review team could not reach a judgement on moderate or severe harm.
Some patients and their families have been severely affected.
One patient received over 100 cycles of chemotherapy, over 13 years, due to the incorrect diagnosis. This patient was later found to have developed leukemia (blood cancer) as a result of prior chemotherapy.
Becky Jones received over 100 cycles of TMZ treatment for around 11 years, due to an incorrect diagnosis of glioblastoma. She was told that she only had between 6-12 months to live. Despite Becky raising concerns regarding her treatment, as scans showed stable results, she was repeatedly told that stopping chemotherapy could be life-threatening.
According to her legal representatives at Brabners, subsequent independent expert assessments concluded that she had most likely been suffering from tumefactive demyelination rather than a brain tumor.
David Bown received TMZ for over 8 years. His family has reported that he suffered significantly from health issues, including problems with his liver and mental health. David’s father described the situation as devastating.
An official apology has been sent out by the UHCW NHS Trust to those affected. It was sent out by Chief Executive Andy Hardy and Chair Sue Noyes.
They admitted that patients were receiving chemotherapy for longer than nationally accepted guidelines recommend. They also admitted that there were opportunities for treatment decisions to be questioned and reviewed that were missed.
In response, they are taking the following actions:
Extending the historical review to include patients treated from 2005 (the year in which national guidelines for TMZ were published).
Requesting independent external clinical reviews for all current patients who were given over 12 cycles of TMZ by Professor Brown.
Collaborating with NHS England to create processes to review deceased patients who received unusual chemotherapy.
Improving clinical management and reviewing systems in place for staff to report issues and raise concerns.
They have also confirmed that all living patients receiving TMZ at the trust have had their care internally reviewed.
As per the BBC, UHCW Chief Executive, Professor Andy Hardy, has said that up to hundreds of patients could have been affected, as they will be reviewing patients treated by Professor Brown from 2005.
Within the review, 83 patients were found to have received prolonged treatment with TMZ from 2017-2023.
Furthermore, law firm Brabners, which represents more than 40 patients affected by the treatment concerns, is calling for an independent public inquiry to establish how the inappropriate treatment continued for so long and why opportunities to intervene were missed.
This case highlights concerns for patient safety, informed consent, and accountability within the NHS. It shows the importance of regular treatment reviews, multidisciplinary management, and good systems in place to raise concerns around clinical practice.
Rh/MF/MSM